Local Pollen Forecast

Detailed pollen forecast for

Today's Level

Pollen Levels

Low 0 – 2.4

Pollen levels between 0 and 2.4 tend to affect very few individuals among the allergy-suffering public.

Low-Medium 2.5 – 4.8

Pollen levels between 2.5 and 4.8 tend to start affecting individuals extremely sensitive to the predominant pollen.

Medium 4.9 – 7.2

Pollen levels between 4.9 and 7.2 will likely cause symptoms for many individuals who suffer from allergies to the predominant pollen types of the season.

Medium-High 7.3 – 9.6

Pollen levels between 7.3 and 9.6 tend to affect a large number of individuals who suffer from the pollen types of the season.

High 9.7 – 12.0

Pollen levels between 9.7 and 12.0 tend to affect most individuals who suffer from the pollen types of the season. Symptoms may become more severe during days with high pollen levels.

Detailed 4-Day Forecast

Enter your ZIP code

  • High
  • Medium-High
  • Medium
  • Low-Medium
  • Low

Predominant Pollen

Symptom relief begins within 24-48 hours after the first dose.

Small Font
Medium Font
Large Font

email

print

Join the OMNARIS Relief is Here Program
Pay Only $11
And pay only $11 every time you fill your prescription.*

*Maximum savings of $50 on up to 12 prescription fills of OMNARIS per year. For qualifying patients. Restrictions apply.
Full Program rules

Why OMNARIS

24/7 relief for all your nasal allergy symptoms, all year long — that's comfortable to take!

Find out more

OMNARIS (ciclesonide) Nasal Spray is for the treatment of nasal allergy symptoms associated with seasonal allergic rhinitis (seasonal allergies) in adults and children 6 years of age and older, and with perennial allergic rhinitis (year-round allergies) in adults and adolescents 12 and older.

Important Safety Information

Patients using corticosteroid drugs that weaken the immune system are more susceptible to infection and should avoid exposure to chickenpox or measles. If you have tuberculosis, eye herpes, or untreated infections of any kind, speak to your doctor before using OMNARIS. Yeast infections of the nose and throat may occur.

Patients who have recently had an ulcer in the nose, trauma to the nose or nasal surgery should not use OMNARIS until healing has occurred. Rare instances of nasal irritation and eye problems have been reported following the use of nasal steroids. Talk with your doctor if you have a history of eye problems or experience a change in vision.

Patients taking higher doses of a nasal steroid than recommended, or certain other at-risk individuals, may experience symptoms of a hormonal imbalance, including very rarely changes in menstruation, acne, and weight gain. Like all steroid nasal sprays, OMNARIS may cause slowed growth in children. The growth of children using OMNARIS should be monitored routinely by a healthcare professional.

The most common side effects that may occur with OMNARIS are headache, nosebleed, sore throat and ear pain.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

For more information, please see the OMNARIS Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. OMNARIS is available by prescription. Ask your healthcare professional if OMNARIS is right for you.

The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. This site is intended for U.S. residents only. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

©2010 Sepracor Inc.and SEPRACOR are registered trademarks of Sepracor Inc.

OMNARIS is a registered trademark of Nycomed GmbH, used with permission.

Sepracor

Bookmark & Share